Overview
The primary purpose of this study is to evaluate safety of lecanemab in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in participants treated with lecanemab.
Eligibility
Inclusion Criteria:
- 18 years or older at consent
- Prior to JOY-ALZ enrollment, the treating physician confirms that the participant is suitable for lecanemab treatment, as per the approved indications in South Korea
- Has an identified study partner who provides separate written informed consent
- Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.
Exclusion Criteria:
- Currently participating in an interventional clinical study
- Has contraindications for lecanemab according to the approved prescribing information in South Korea